Document Detail


Heart valve replacement for patients with end-stage renal disease in Japan.
MedLine Citation:
PMID:  20190702     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is some controversy regarding the choice of prosthetic valves in patients with heart disease and concomitant end-stage renal disease requiring chronic dialysis. Dialysis patients tend to have a short life expectancy. In Japan, the 1-year survival of the dialysis patients was 80% in the 1980s, but exceeds 85% in the 2000s. The 5-year survival has been 54%-60% for the past 20 years. In addition, the 10-year and 15-year survivals have been 35%-42% and 23%-31%, respectively. However, in the United States, the 5-year survival had only improved to 35% among patients who started dialysis between 1996 and 2000, and the life expectancies of chronic dialysis patients in their sixth, seventh and eighth decades is 5.3-6.2 years, 3.8-4.5 years, and 2.7-3.2 years, respectively. The life expectancy of dialysis patients in Japan is thus better than that of patients in the United States. Some surgeons prefer to use bioprosthetic valves because of a high rate of hemorrhagic complications in dialysis patients. They are hesitant to use anticoagulation therapy in dialysis patients with mechanical valves. Others prefer mechanical valves because of the potential for early structural dysfunction of bioprosthetic valves implanted in the dialysis patients with abnormal calcium metabolism, which can cause calcium deposition on the bioprosthetic valves during the early postoperative period. The life expectancy of dialysis patients in Japan is relatively high. The potential risk of early calcification of bioprosthetic valves should be taken into account when choosing prosthetic heart valves for these patients in Japan.
Authors:
Yoshio Misawa
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia     Volume:  16     ISSN:  2186-1005     ISO Abbreviation:  Ann Thorac Cardiovasc Surg     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-03-01     Completed Date:  2010-05-28     Revised Date:  2012-06-18    
Medline Journal Info:
Nlm Unique ID:  9703158     Medline TA:  Ann Thorac Cardiovasc Surg     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  4-8     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use
Bioprosthesis
Heart Valve Diseases / complications,  mortality,  surgery*
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation* / adverse effects,  instrumentation
Humans
Japan
Kidney Failure, Chronic / complications*,  mortality,  therapy
Life Expectancy
Patient Selection
Prosthesis Design
Prosthesis Failure
Renal Dialysis / adverse effects
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticoagulants

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The acquisition of reading fluency in an orthographically transparent language (Italian): an eye mov...
Next Document:  After omental flap transposition, respiratory function and exercise capacity decrease.